TITLE

Radiation oncology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS82
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Watchful waiting or watchful progression?; Prostate-specific antigen doubling times and clinical behavior in early untreated prostate cancer,' by Duncan McLaren et al.
ACCESSION #
9708175990

 

Related Articles

  • Protein Patterns May Aid Prostate Cancer Detection.  // Ascribe Newswire: Medicine;10/15/2002, p5 

    A test that detects a specific pattern of proteins in blood may distinguish benign prostate conditions from prostate cancer more effectively than the current biomarker for the disease: protein specific antigen. According to a report in the October 16 issue of the "Journal of the National Cancer...

  • Prostate cancer: Emerging concepts. Garnick, Marc B.; Fair, William R. // Annals of Internal Medicine;7/15/96, Vol. 125 Issue 2, p118 

    Part I. Describes research advances in identifying prostate cancer antigens (PSA). Interpretation of PSA values; Challenges in managing localized PSAs; Treatment management of patients with clinically organ-confined prostate cancer.

  • Prostate cancer incidence rates have started to decrease in central Italy. Crocetti, Emanuele; Ciatto, Stefano; Buzzoni, Carlotta; Zappa, Marco // Journal of Medical Screening;Mar2010, Vol. 17 Issue 1, p50 

    The widespread use of prostate-specific antigen (PSA) testing has dramatically changed the epidemiology of prostate cancer. Growing incidence rates have been documented in almost all western countries following the increased usage of PSA screening. In the United States after a period of huge...

  • What's hot in the prostate? Belldegrun, Edited by Arie // Prostate Cancer & Prostatic Diseases;2001, Vol. 4 Issue 2, p67 

    Discusses issues concerning prostate cancer. Update on the European Randomized Study of Screening for Prostate Cancer; Prostate-specific antigen screening strategies; Proposal to modify the Gleason grading system; Prospective trial of PC-SPES in progressive prostate cancer.

  • The clinical utility, benefits, and limitations of percent free PSA testing. Potter, Steven R.; Partin, Alan W. // Contemporary Urology;Aug99, Vol. 11 Issue 8, p15 

    Focuses on the role of percent free prostate specific antigen (PSA) in patient management and the early detection of prostate cancer in the United States. Molecular forms of PSA; Comparison of the predictive values of PSA, age-adjusted PSA, transrectal ultrasonography findings, PSA density and...

  • Inappropriate Drug Prescribed For Early Prostate Cancer.  // HealthFacts;May2002, Vol. 27 Issue 5, p1 

    Provides information on a study which supported the effectiveness of the use of the prostate-specific antigen screening test for the treatment of prostate cancer in men.

  • Interpreting the PSA--the key to adequate prostate cancer screening. E.B. // Medical Update;Dec96, Vol. 20 Issue 6, p1 

    Presents information on the prostate-specific antigen (PSA) test used in diagnosing prostate cancer. Production of PSA in the epithelial cells of the prostate gland; Problems with the use of the test.

  • Prostate-specific antigen: A treatment for prostate cancer? Lucas, Beverly D. // Patient Care;12/15/1999, Vol. 33 Issue 20, p12 

    Discusses the physiological effect of increased prostrate-specific antigen (PSA) level. Emphasis on the non protein-specific nature of PSA; Existence of PSA in breast, lung and uterine cancer patients; Ability of PSA to synthesize anti-angiogenic proteins for fighting cancer.

  • PSA levels after radiotherapy: How low must they go? McNeil, Caroline // JNCI: Journal of the National Cancer Institute;6/19/96, Vol. 88 Issue 12, p791 

    Reports on the treatment of prostate cancer. Controversy surrounding the crucial prostate-specific antigen (PSA) level to reach after radiotherapy; Needed decrease of PSA to undetectable levels after prostate surgery, for patients to have a chance of cure; Radiotherapy versus surgery in the...

  • Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth... Thalmann, George N.; Sikes, Robert A. // JNCI: Journal of the National Cancer Institute;6/19/96, Vol. 88 Issue 12, p794 

    Assesses the effect of suramin on the growth of the androgen-dependent human prostate cancer cell line LNCaP and its androgen-independent subline C4-2 both in vivo and in vitro. Materials and method of study; Statistical analysis; In vivo and in vitro assessment of suramin activity.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics